Jorge Ravelo

To seek and maintain full-time position that offers professional challenges utilizing interpersonal skills, excellent time management and problem-solving skills.

Dedicated clinical research professional with history of meeting company goals utilizing consistent and organized practices. Skilled in working under pressure and adapting to new situations and challenges to best enhance the organizational brand.

Hardworking and passionate job seeker with strong organizational skills eager to secure entry-level Clinical Research position. Ready to help team achieve company goals.

Experienced Clinical Researcher with over 17 years of experience performing autoimmune sponsored clinical trials.

Expertise in Biologic therapy Excellent reputation for resolving problems and improving customer satisfaction.

Certified Principal Investigator-Association of Clinical Research Professionals,valid until Nov 2023

I use to travel everywhere using my bycicle, it makes free, healthy and happy. I am eager to start biking in Calgary.

I would like to travel a lot, I enjoy natural landscapes, food, people, culture; it would be better accompanied by family and friends 

I love Netflix series, for instance I have enjoyed all Harlan Coben's series, I also like historical series like Freud, Last Kingdom, Rome, Hitler's circle of evil, Barbarians, and many others  

1. A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants with Systemic Lupus Erythematosus (ALLEGORY) NCT04963296, started Feb2022, ongoing World top enroller.

2. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) NCT04294667, started July 2021, ongoing

3. A Phase 1b/2 Study of KZR-616 in Patients with Systemic Lupus Erythematosus with and Without Nephritis. NCT03393013, start October 2021, finished on Oct 2022.World top enroller.Member of American Advisory Board for Phase III KZR 616 Study design

4. A phase III, Randomized, Double-Blind, Placebo-controlled, multicentre Study to evaluate the efficacy and safety of Obinutuzimab in patients with ISN/RPS 2003 class III or IV Lupus Nephritis CA41705 NCT04221477, started enrolling Sep 2020. Roche Internal Audit on June 2022, recommended: continue enrolling. Ongoing Study

5. A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care. NCT03371251. Started December 2019 ended sep 2020

6. A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE). NCT02975336, Started November 2017, ended 2020 with 2nd year Extension phase.

7. A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus. NCT02804763, started in July 2017, ended Dec 2018

8. A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis. NCT02547922, started in October 2016, enrolling for 2nd year extension

a. Special Mention: World Top Enroller

b. Sponsor Auditory 15 to 17 Aug 2017: Recommendation: Continue Enrolling

9. A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis.

NCT01663623 From 18Mar2014 until 21mar2017

a. National Top Enroller: 5 patients, all patients completed study

10. A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimumab and MTX. NCT01764997.From 19may2014 until 16jul2015.

11. A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546-1145 in Adults with Systemic Lupus Erythematosus. NCT01753193 From 13jan2014 to 13jul2017

a. National Top Enroller

12. A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546-1013 in Subjects with Systemic Lupus Erythematosus NCT01438489 From 27jun2012 until 27oct2013

13. A Randomized, Double Blind, Parallel-group Study of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen NCT00346216. From 14apr2008 until 28nov2016

a. National Top Enroller

b. Sponsor Auditory Jul 2012 Satisfactory, recommendation: Continue Enrolling.

Publications:

1.Journal of Clinical Rheumatology; 27(SUPPL 1): S10-S11, 2021.

2. doi: https://preprints.scielo.org/index.php/scielo/preprint/view

/1314

3. https://doi.org/10.15381/anales.v81i2.17858

4. An Fac Med Vol. 81 Núm. 2 (2020) DOI: https://doi.org/10.15381/anales.v81i2.17893

5. Journal of Clinical Rheumatology Aug 2006 Vol. 12 Issue 4

Supplement

6. Revista Colombiana de Reumatología 2005 Vol. 12 No. 4